Abstract
This article describes the synthesis and the biological evaluation of two sets of benzothiazole derivatives bearing at C-2 an arylamide (1a–e, 2a–e) or an arylurea (3a–d, 4a–d) moiety. Five compounds (3d and 4a–d) were selected and screened by the National Cancer Institute for the in vitro primary anticancer assay against a panel of 60 human tumor cell lines. Compounds 4a and 4c showed interesting anticancer activities, more marked for compound 4c. All compounds were also submitted to a preliminary in vitro assay as potential inhibitors of the ubiquitin-activating enzyme (E1), but they lacked significant activity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aiello S, Wells G, Stone EL, Kadri H, Bazzi R, Bell DR, Stevens MFG, Matthews CS, Bradshaw TD, Westwell AD (2008) Synthesis and biological properties of benzothiazole, benzoxazole, and chromen-4-one analogues of the potent antitumor agent 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (PMX 610, NSC 721648). J Med Chem 51:5135–5139
Boyd MR (1997) Preclinical screening, clinical trials, and approval. Humana Press, Totowa, NJ
Boyd MR, Paull KD (1995) Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Dev Res 34:91–109
Brantley E, Antony S, Kohlhagen G, Meng LH, Agama K, Stinson SF, Sausville EA, Pommier Y (2006) Anti-tumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces single-strand breaks and DNA-protein cross-links in sensitive MCF-7 breast cancer cells. Cancer Chemother Pharmacol 58:62–72
Das J, Moquin RV, Lin J, Liu C, Doweyko AM, DeFex HF, Fang Q, Pang S, Pitt S, Shen DR, Schieven GL, Barrish JC, Wityak J (2003) Discovery of 2-amino-heteroaryl-benzothiazole-6-anilides as potent p56lck inhibitors. Bioorg Med Chem Lett 13:2587–2590
Guédat P, Colland F (2007) Patented small molecule inhibitors in the ubiquitin proteasome system. BMC Biochemistry 8(Suppl 1):S14
Jimonet P, Audiau F, Barreau M, Blanchard JC, Boireau A, Bour Y, Coléno MA, Doble A, Doerflinger G, Huu GD, Donat MH, Duchesne JM, Ganil P, Guérémy C, Honoré H, Just B, Kerphirique R, Gontier S, Hubert P, Laduron PM, Le Blevec J, Meunier M, Miquet JM, Nemecek C, Pasquet M, Piot O, Pratt J, Rataud J, Reibaud J, Stutzmann JM, Magnani S (1999) Riluzole series. Synthesis and in vivo “antiglutamate” activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines. J Med Chem 42:2828–2843
Lion CJ, Matthews CS, Wells G, Bradshaw TD, Stevens MFG, Westwell AD (2006) Antitumour properties of fluorinated benzothiazole-substituted hydroxycyclohexa-2,5-dienones (“quinols”). Bioorg Med Chem Lett 16:5005–5008
Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J, Boyd M (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83:757–766
Mortimer CG, Wells G, Crochard JP, Stone EL, Bradshaw TD, Stevens MFG, Westwell AD (2006) Antitumor benzothiazoles. 26. 2-(3,4-Dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines. J Med Chem 49:179–185
Parlati F, Ramesh UV, Singh R, Payan DG, Lowe R, Look GC Benzothiazole and thiazole[5,5-b] pyridine compositions and their use as ubiquitin ligase inhibitors Publication No. WO 2005/037845
Sankaranarayanan A, Raman G, Busch C, Schultz T, Zimin PI, Hoyer J, Kohler R, Wulff H (2009) Naphtho[1, 2-d] thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol Pharmacol 75:281–295
Song EY, Kaur N, Park MY, Jin Y, Lee K, Kim G, Lee KY, Yang YS, Shin JH, Nam KY, No KT, Ha G (2008) Synthesis of amide and urea derivatives of benzothiazole as Raf-1 inhibitor. Eur J Med Chem 43:1519–1524
Wells G, Bradshaw TD, Diana P, Seaton A, Shi D, Westwell AD, Stevens MFG (2000) Antitumour benzothiazoles. Part 10: The synthesis and antitumour activity of benzothiazole substituted quinol derivatives. Bioorg Med Chem Lett 10:513–515
Xu GW, Ali M, Wood TE, Wong D, Maclean N, Wang X, Gronda M, Skrtic M, Li X, Hurren R, Mao X, Venkatesan M, Beheshti Zavareh R, Ketela T, Reed JC, Rose D, Moffat J, Batey RA, Dhe-Paganon S, Schimmer AD (2010) The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood 115:2251–2259
Yoshida M, Hayakawa I, Hayashi N, Agatsuma T, Oda Y, Tanzawa F, Iwasaki S, Koyama K, Furukawa H, Kurakata S, Sugano Y (2005) Synthesis and biological evaluation of benzothiazole derivatives as potent antitumor agents. Bioorg Med Chem Lett 15:3328–3332
Acknowledgments
This study was financially supported by MIUR (Ministero dell’Istruzione, dell’Università e della Ricerca), PRIN2008 grant no. 200879X9N9. The authors thank the OICR medicinal chemistry platform, Toronto, Canada, for providing reagents for the in vitro E1-assay, and the Division of Cancer Research, National Cancer Institute, Bethesda, Maryland, for performing the antitumor tests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Caputo, R., Calabrò, M.L., Micale, N. et al. Synthesis of benzothiazole derivatives and their biological evaluation as anticancer agents. Med Chem Res 21, 2644–2651 (2012). https://doi.org/10.1007/s00044-011-9789-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-011-9789-8